Humana Inc (HUM)
Official siteHEALTHCARE • HEALTHCARE PLANS • NYSE
Market Cap: $55.40B
Last updated: Nov 17, 2026 at 4:44 PM ET
Humana Inc (HUM) Statistics
Humana (HUM) has a market cap of $55.40B and an enterprise value of $60.97B. Revenue grew 22.02% over the last 12 months from the 12 months before. Its trailing P/E of 33.4x is above its 10-year median of 19.7x.
Total Valuation
Enterprise value is 10.05% above the market cap, as debt exceeds cash.
| Market Cap | $55.40B |
|---|---|
| Enterprise Value | $60.97B |
| Latest price (Nov 17, 2026) | $443.43 |
Key Dates
The next earnings report is expected on Feb 9, 2027, covering the quarter ending Dec 31, 2026. The next ex-dividend date is Dec 24, 2026.
| Next Earnings Date | Feb 9, 2027 (expected) |
|---|---|
| Last Earnings Date | Nov 6, 2026 |
| Next Ex-Dividend Date | Dec 24, 2026 |
| Next Payment Date | Jan 29, 2027 |
| Fiscal Year End | December |
Valuation Ratios
Sales and book value multiples are 0.3x and 2.8x. Its year-end P/E ranged from 15.0x to 22.5x from 2016 to 2025.
| P/E Ratio | 33.4x |
|---|---|
| Forward P/E | 47.0x |
| P/S Ratio | 0.3x |
| Forward P/S | 0.3x |
| P/B Ratio | 2.8x |
| P/TBV Ratio | 6.4x |
| P/FCF Ratio | 17.0x |
| P/OCF Ratio | 14.8x |
| PEG Ratio | 2.3 |
Enterprise Valuation
Counting debt and cash, the company is valued at 18.0x EBITDA and 18.7x free cash flow.
| EV / Earnings | 48.3x |
|---|---|
| EV / Sales | 0.4x |
| EV / EBITDA | 18.0x |
| EV / EBIT | 24.3x |
| EV / FCF | 18.7x |
Price Statistics
The stock is up 89.06% over 52 weeks and trades 8.14% above its 50-day average.
| Beta (1Y) | 0.54 |
|---|---|
| 52-Week Change | +89.06% |
| 1-Month Change | +7.08% |
| 3-Month Change | +17.55% |
| 6-Month Change | +43.12% |
| 5-Year Change | -10.51% |
| 10-Year Change | +141.65% |
| Total Return (1Y) | +90.57% |
| Total Return (3Y CAGR) | -2.69% |
| Total Return (5Y CAGR) | +0.85% |
| Return vs SPY (1Y) | +79.94% |
| Max Drawdown (1Y) | -42.36% |
| Max Drawdown (3Y) | -67.56% |
| Sharpe Ratio (1Y) | 1.39 |
| Correlation with SPY (1Y) | 0.16 |
| 50-Day Average | $410.04 |
| 200-Day Average | $319.10 |
| 52-Week Range | $161.56 to $462.87 |
| RSI (14 Days) | 58.1 |
| Average Volume (20 Days) | 1.56M |
The 5 and 10 year changes compare month-end closes, adjusted for splits, through Oct 2026.
Financial Position
Current assets cover 1.65x current liabilities, and total debt is 0.66x shareholder equity.
| Current Ratio | 1.65x |
|---|---|
| Quick Ratio | 1.65x |
| Debt / Equity | 0.66x |
| Debt / EBITDA | 3.83x |
| Debt / FCF | 3.98x |
| Interest Coverage | 3.33x |
Returns and Efficiency
Return on invested capital is 6.06% over the last 12 months, against a 5-year average of 9.17%.
| Return on Equity (ROE) | 6.70% |
|---|---|
| Return on Assets (ROA) | 2.20% |
| Return on Invested Capital (ROIC) | 6.06% |
| Return on Capital Employed (ROCE) | 7.54% |
| ROE (5Y Average) | 13.21% |
| ROA (5Y Average) | 4.69% |
| ROIC (5Y Average) | 9.17% |
| Asset Turnover | 2.88x |
| Receivables Turnover | 36.02x |
Taxes
Income tax took 24.20% of pretax income over the last 12 months.
| Income Tax (TTM) | $424.00M |
|---|---|
| Effective Tax Rate | 24.20% |
Scores
HUM has an Altman Z-Score of 4.75, in the safe zone above 2.99, and a Piotroski F-Score of 6 of 9, in the average band of 3 to 7.
Altman Z-ScoreDistress below 1.81Safe above 2.99
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Altman Z-Score | 4.75 |
|---|---|
| Altman Z Zone | Safe |
| Piotroski F-Score | 6 of 9 |
| Piotroski Strength | Average |
Income Statement
Revenue was $154.19B over the last 12 months.
| Revenue | $154.19B |
|---|---|
| Revenue Growth (YoY) | +22.02% |
| Gross Profit | $20.06B |
| Operating Income | $2.38B |
| Pretax Income | $1.75B |
| Net Income | $1.26B |
| EBITDA | $3.27B |
| EBIT | $2.50B |
| Reported EPS (TTM) | $13.26 |
Trailing 12 months through Sep 30, 2026.
Balance Sheet
Shareholder equity funds 32.86% of the $57.28B in total assets.
| Cash and Equivalents | $6.93B |
|---|---|
| Total Debt | $12.50B |
| Net Debt | $5.57B |
| Net Debt Per Share | $46.37 |
| Working Capital | $15.56B |
| Shareholder Equity | $18.82B |
| Book Value Per Share | $156.74 |
| Tangible Book Value | $8.28B |
| Tangible Book Per Share | $68.92 |
| Total Assets | $57.28B |
| Total Liabilities | $38.40B |
Balance sheet as of Sep 30, 2026.
Cash Flow
After $592.00M of capital spending, operating cash flow left $3.14B of free cash flow.
| Operating Cash Flow | $3.73B |
|---|---|
| Capital Expenditures | $592.00M |
| Free Cash Flow | $3.14B |
| FCF Per Share | $26.14 |
| Depreciation and Amortization | $763.00M |
| Dividends Paid | $429.00M |
| Share Repurchases | $152.00M |
Trailing 12 months through Sep 30, 2026.
Margins
The operating margin is 1.54%, against a 5-year average of 3.18%.
| Gross Margin | 13.01% |
|---|---|
| Operating Margin | 1.54% |
| Pretax Margin | 1.14% |
| Net Margin | 0.82% |
| EBITDA Margin | 2.12% |
| EBIT Margin | 1.62% |
| FCF Margin | 2.04% |
| Gross Margin (5Y Average) | 16.23% |
| Operating Margin (5Y Average) | 3.18% |
| Net Margin (5Y Average) | 2.17% |
Growth
Revenue grew 11.77% a year over 3 years, and EPS fell 12.09% a year.
| Revenue Growth (3Y CAGR) | +11.77% |
|---|---|
| Revenue Growth (5Y CAGR) | +10.94% |
| EPS Growth (3Y CAGR) | -12.09% |
| EPS Growth (5Y CAGR) | -1.78% |
| FCF Growth (3Y CAGR) | -52.28% |
| FCF Growth (5Y CAGR) | -39.63% |
| Operating Income Growth (3Y CAGR) | -10.72% |
| Book Value Per Share Growth (2Y CAGR) | +5.12% |
| Tangible Book Per Share Growth (2Y CAGR) | +9.93% |
Dividends and Yields
HUM pays out 11.40% of earnings as dividends.
| Dividend Per Share (Annual) | $3.54 |
|---|---|
| Dividend Yield | 0.80% |
| Payment Schedule | Quarterly |
| Dividend Growth (3Y CAGR) | +3.97% |
| Dividend Growth (5Y CAGR) | +7.20% |
| Payout Ratio | 11.40% |
| FCF Payout Ratio | 13.67% |
| Earnings Yield | 2.99% |
| FCF Yield | 5.89% |
| Buyback Yield | 0.29% |
| Shareholder Yield | 1.09% |
Peer Position
Against 12 similar companies, HUM has the 4th highest P/E and the 7th highest P/S.
P/E RatioPeer median 16.7x
P/S RatioPeer median 0.4x
ROICPeer median 9.34%
Revenue Growth (Trailing 4 Quarters, YoY)Peer median +7.15%
Dividend YieldPeer median 0.41%
| P/E Ratio | 33.4x vs 16.7x median |
|---|---|
| P/S Ratio | 0.3x vs 0.4x median |
| ROIC | 6.06% vs 9.34% median |
| Revenue Growth (Trailing 4 Quarters, YoY) | +22.02% vs +7.15% median |
| Dividend Yield | 0.80% vs 0.41% median |
Analyst Forecast
Consensus estimates put revenue growth at 15.70% and EPS growth at 2.95% a year over the next 2 fiscal years.
| Revenue Growth Forecast (2Y CAGR) | +15.70% |
|---|---|
| EPS Growth Forecast (2Y CAGR) | +2.95% |
Price Target
Analyst price targets are part of paid GNG plans. See plans
GNG Valuation
| GNG view | Fairly valued |
|---|
GNG fair value is part of GNG Pro. See plans
Frequently Asked Questions About HUM
What is HUM's market cap?
Humana has a market cap of $55.40B. Its enterprise value, which adds debt and subtracts cash, is $60.97B.
What is HUM's P/E ratio?
Humana has a trailing P/E ratio of 33.4x and a forward P/E of 47.0x.
How many shares of HUM are outstanding?
Humana has 120.10M shares outstanding. The count is down 0.14% from a year earlier.
Does HUM pay a dividend?
Yes. Humana pays $3.54 a share a year, a dividend yield of 0.80%.
How much debt does HUM have?
Humana has $12.50B of total debt and $6.93B of cash and equivalents, a net debt position of $5.57B.
HUM pages: Overview, Dividends, Charting, Earnings, Forecast, Financials, Statistics, Valuation, Competitors